Eastman Chemical Company (EMN) Q2 2024 earnings summary

Executive summary

• Achieved strong Q2 2024 results with 2% year-over-year sales growth to $2.36 billion, led by Advanced Materials and higher sales volume/mix, and a 300-basis-point sequential margin improvement through volume/mix and operating leverage.

• Methanolysis plant is operational, producing on-spec food-grade Tritan with 75% recycled content, ramping up utilization rates, and expected to contribute ~$50M incremental EBITDA in 2024.

• Customer inventory destocking largely complete, with end-market demand stabilizing at lower levels; premium pricing and innovation wins are driving growth despite a weak macro environment.

• Returned $195 million to shareholders in Q2 2024 through share repurchases and dividends, with $300 million planned for FY24.

• Supported circular economy initiatives, including new recycling partnerships and successful launch of Aventa cellulosic packaging.

Financial highlights

• Q2 2024 revenue was $2.36 billion, up from $2.32 billion in Q2 2023; adjusted EBIT was $353 million (14.9% margin), and adjusted EPS was $2.15.

• Net earnings attributable to Eastman were $230 million in Q2 2024; diluted EPS was $1.94.

• CapEx for 2024 is set at $650M–$700M, with $300M spent in the first half, focused on molecular recycling and growth initiatives.

• Share repurchases increased to $300M for the year, with $100M completed in Q2 2024.

• Forecasted FY24 operating cash flow is approximately $1.4 billion.

Outlook and guidance

• FY24 adjusted EPS expected in the range of $7.40 to $7.85; operating cash flow forecasted at ~$1.4 billion.

• Full-year guidance midpoint assumes no improvement in economic activity, with half of revenue expected to see modest 2–3% growth and half flat.

• Kingsport methanolysis facility expected to contribute ~$50M incremental EBITDA in 2024, with a run rate target of $150M EBITDA by end of 2025.

• Capital expenditures for FY24 expected at $650–$700 million; share repurchases for FY24 expected at ~$300 million.

• No significant end-market demand improvement expected in H2 2024; focus remains on innovation-driven growth and cost discipline.